FDA's ANDA Approvals
Generic drug approvals and tentative approvals in early March.
You may also be interested in...
Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage.
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.